Helixmith

Helixmith Co., Ltd is a biotechnology company based in Seoul, South Korea, focused on discovering and developing biopharmaceuticals for various human diseases. The company has a diverse pipeline that includes novel biologics and herbal therapeutics targeting cardiovascular diseases, cancer, and immune disorders. Its flagship product, VM202, is a DNA-based drug aimed at treating cardiovascular and neurological conditions. Additionally, Helixmith is developing VM206, a therapeutic cancer vaccine for HER2/neu positive breast or ovarian cancer, and VM501, which targets chemotherapy-induced thrombocytopenia. The company is engaged in ongoing clinical studies in the United States, Korea, and China. Helixmith was formerly known as ViroMed Co., Ltd before rebranding in April 2019 and has been incorporated since 1996.